Peritonoids (B, D, F) resemble the tumor cell morphology of
the native tumor (A, C, E) and express intestinal epithelial
markers (A-B H&E, C-D CDX2, E-F
CK20). Scale bar 100μm. (G) Schema depicting our precision
medicine screening platform to guide patient-specific treatment for patients
with worst prognosis CRC. Peritonoids and peripheral blood mononuclear cells
undergo next-generation whole exome sequencing (WES) to identify genetic
alterations found in the tumor and germline of each patient. This is combined
with medium-throughput drug panel testing to identify specific drug
sensitivities for each patient. Results are presented to the medical oncology
team to provide treatment change options should patients exhaust standard care
chemotherapy.